First Results in an MR Imaging-Compatible Canine Model of Acute Stroke

A. Shaibani, S. Khawar, W. Shin, T.A. Cashen, B. Schirf, M. Rohany, S. Kakodkar and T.J. Carroll

AJNR Am J Neuroradiol 2006, 27 (8) 1788-1793
http://www.ajnr.org/content/27/8/1788
First Results in an MR Imaging-Compatible Canine Model of Acute Stroke

BACKGROUND AND PURPOSE: The purpose of this work was to develop an MR imaging-compatible animal model of reversible embolic stroke. We hypothesize that real-time MR imaging of the brain can be performed during stroke thrombolysis and can provide real-time feedback and guidance on the success of thrombolysis.

METHODS: Embolic strokes were induced in 5 adult dogs by the use of autologous blood clots, with a sixth dog serving as an experimental control. Serial MR anatomic and physiologic imaging was performed to track the evolution of the stroke. The apparent diffusion coefficient (ADC) and quantitative cerebral blood flow (qCBF) were compared in the normal and stroke regions. During and after the administration of a chemical thrombolytic agent, MR imaging was performed to assess the outcome of the treatment.

RESULTS: Strokes were successfully created in 5 animals. No ADC or qCBF changes were observed in the control animal. Both ADC and qCBF values were found to be significantly different in the region affected by the stroke. Restoration of flow was observed in 1 case.

CONCLUSION: We have successfully implemented an MR imaging-compatible canine model of reversible embolic stroke.

Strokes are the third leading cause of death in the United States, with estimates of death and disability ranging from 300,000 to 731,000 annually. The goal of current imaging and diagnosis of stroke is to identify brain tissue that is hypoperfused but salvageable, the so-called “ischemic penumbra.” An effective means to reduce the neurologic deficit from stroke is to restore blood flow to the ischemic penumbra. In a number of multicenter trials, thrombolysis has been shown to be successful at restoring blood flow. However, a high rate of cerebral hemorrhage (10%–15%) has prompted the Food and Drug Administration to limit the use of IV thrombolytic therapy to within 3 hours of onset of symptoms. The restrictive 3-hour time window limits the administration of thrombolytic agents to only 1%–2% of patients presenting with acute ischemic stroke. Extending this window of opportunity for thrombolysis by identifying those patients who would still benefit from thrombolysis is an active area of research worldwide.

The utility of any treatment that intends to extend the treatment window, or study alternative approaches to chemical thrombolysis, must be evaluated in a realistic and reproducible model of acute stroke. We report on the implementation of a canine model of reversible acute stroke using autologous blood clots. The rationale for conducting these experiments in a canine model are several. First, to achieve optimal resolution for MR imaging techniques, the subject brain has to be larger than that found in rodent or feline models. Second, the canine model is well established for the study of cerebrovascular diseases such as stroke and vasospasm. Finally, the vascular anatomy of the dog lends itself to a more targeted arterial embolization (compared with the porcine model, where the vascular rete formation prevents directed embolization).

Given the increasingly important role of MR perfusion and diffusion imaging in understanding the pathophysiology of stroke, this model has been designed to be completely MR imaging-compatible. We have tested this model in both 1.5T and 3T clinical MR imaging scanners. We hypothesize that MR imaging can be successfully used to monitor and guide thrombolysis in real time. A secondary objective is to measure quantitative cerebral blood flow (qCBF) in a well-controlled stroke model with the use of a recently reported method for absolute quantification of cerebral perfusion using MR imaging.

Materials and Methods
We have developed a canine model of embolic stroke by the catheter-directed injection of autologous blood clots into the internal carotid artery (ICA) that is reversible via intraarterial administration of recombinant tissue plasminogen activator (rtPA) administration. Autologous blood clots were injected directly into the intracranial vasculature via an angiographic catheter to create physiologically “accurate” strokes. Occlusion of the ipsilateral middle cerebral artery (MCA) was confirmed and documented using digital subtraction angiography (DSA). The perfusion defect and evolution of the infarct were evaluated with serial MR perfusion and diffusion imaging. After thrombolysis, additional perfusion and diffusion images were acquired to evaluate the outcome of the treatment.

Animal Preparation
Animal studies were conducted under the guidelines of the local Animal Care and Use Committee (ACUC). All animals were housed indoors under standardized conditions. The dogs were fasted with full access to water for 8 hours before the procedure to minimize anesthesia complications. Six adult dogs (weight = 21.03 ± 2.31 [mean ± SD]) were preanesthetized with an injection of Innovar (1-mL intramuscular injection) before being transported to our imaging facility. A vein in the foreleg was cannulated (20–22-gauge) for venous access. Anesthesia was induced with propofol (5–7.5 mg/kg intravenous administration).
stroke was induced was studied using a 1.5 T scanner, but the remaining experiments were performed using a 3T scanner. Three dogs, all of which were scanned on the 3T MR imaging scanner, were treated with rtPA.

**MR Imaging Studies**

Five dogs were placed supine head first in a 3T whole-body scanner (Trio; Siemens Medical Solutions, Erlangen, Germany) using an 8-channel receive-only head coil (Siemens Medical Solutions) for signal intensity reception. A sixth dog was scanned in a 1.5T whole-body MR imaging scanner (Sonata; Siemens Medical Solutions) to provide a baseline measurement for comparison with our high field imaging results. In the experiment performed at 1.5T, a single-channel birdcage coil was used because an 8-channel head coil was not available at the time. The MR imaging protocol consisted of anatomic imaging (T1; T2; fluid-attenuated inversion recovery and 3D T1-weighted images) as well as serial perfusion- (PWI) and diffusion-weighted images (DWI) (Table 1). The perfusion imaging protocol included the acquisition of preinjection and postinjection T1 maps. Changes in T1 resulting from the injection of gadolinium were used to quantify cerebral perfusion after correcting for water exchange effects.11,15

Serial DWI/PWI images were acquired at 30-minute intervals to track the evolution of diffusion changes in the region affected by the stroke and to detect any perfusion changes in response to treatment. The DWI parameters were adapted from the standard clinical protocol used at our site. Because of anatomic differences between humans and dogs, the DWI/PWI images were acquired in the coronal plane. The parameters for the DWI images were: repetition time (TR)/echo time (TE) = 3000/97 ms, bandwidth (BW) = 1220 Hz/pixel, field of view (FOV) = 148 × 148 cm, b-values = 0, 500, 1000 s/mm², matrix = 128 × 128, 15 5-mm sections were acquired with no skip between sections.

The PWI images were colocalized to the central sections of the diffusion images using the scanner’s scan prescription tools. The PWI scans were adapted from the clinical protocol used at our site (2D, gradient-echo echo-planar imaging (EPI), TR/TE = 1150/52 ms, BW = 1260 Hz/pixel, 9–10 5-mm sections, 50 phases). For perfusion images, 0.1 mmol/kg body weight of a gadolinium-based contrast agent (Magnestil; Berlex, Princeton, NJ) was injected at 2.0 mL/s through the catheter placed in the left atrium, followed by a saline injection (15 mL at 2 mL/s) to flush the line.

In 3 dogs, chemical thrombolysis of the clot was attempted by intraarterial injection into the catheter placed in the ICA. Thrombolytic therapy was performed using a 2-mg bolus injection of rtPA.

<table>
<thead>
<tr>
<th>Table 1: MR imaging protocol</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Perfusion Weighted</strong></td>
</tr>
<tr>
<td><strong>TR (ms)</strong></td>
</tr>
<tr>
<td><strong>TE (ms)</strong></td>
</tr>
<tr>
<td><strong>Field of view (mm)</strong></td>
</tr>
<tr>
<td><strong>Matrix</strong></td>
</tr>
<tr>
<td><strong>No. of sections</strong></td>
</tr>
<tr>
<td><strong>Thickness (mm)</strong></td>
</tr>
<tr>
<td><strong>Echo-planar imaging factor</strong></td>
</tr>
<tr>
<td><strong>b value (s/mm²)</strong></td>
</tr>
<tr>
<td><strong>Bandwidth (Hz/pixel)</strong></td>
</tr>
</tbody>
</table>

* Values of the 1.5T experimental are shown in parentheses.  † Fifty phases acquired.
(Actove; Genentech, South San Francisco, Calif), followed by a 6-mg infusion performed over 45 minutes. Upon completion of the rtPA infusion, a final DWI/PWI image set was acquired. The dogs were euthanized.

**Image Analysis**

During the imaging experiments, the stroke and its location were determined based on diffusion and perfusion changes using parametric images that were available from the scanner’s processing tools. The prolongation of the time to peak contrast enhancement (TTP) and the mean apparent diffusion coefficient values for the infarct region were evaluated 2 hours 30 minutes after the onset of stroke.⁶ The stroke region was defined as hyperintense on TTP images and a 0.2-mm² region of interest (ROI) was placed to cover the corresponding region on the ADC map. The ADC in the normal contralateral brain parenchyma was measured on the same section of the ADC map to serve as an internal control. Mean ADC and SDs were recorded from the normal contralateral brain region on the ADC map. The ADC in the normal contralateral brain region was significantly different (P < .05) than the normal contralateral values (1.5T, stroke* 6.22 ± 3.36, 3T, stroke 8.28 ± 2.31, P = .0007).

ROI analysis of the stroke and contralateral normal parenchyma are shown in Table 2. The mean values for qCBF in the stroke and contralateral normal ROIs were 7.22 ± 4.90 mL/100 g-min (mean ± SD) and 42.25 ± 8.64 mL/100 g-min, respectively. These differences were found to be statistically significant (P < .0007) (Fig 3).

In 3 experiments, we attempted chemical thrombolysis. Recanalization, defined as the restoration of blood flow to the affected area, was observed in 1 case. Figure 4 demonstrates the pretreatment and posttreatment images in the experiment in which recanalization was observed. Figure 4A shows prolonged TTP in the affected region with concomitant reduced ADC in the same region (Fig 4B) in images acquired 2 hours post ictus. After treatment, the region demonstrating prolonged TTP was reduced in volume (Fig 4C), indicating restored perfusion pressure in that region. Postprocessed images of qCBF calculated from the images before and after administration of rtPA show that perfusion has improved in the stroke region (Fig 4E, -F, respectively).

**Discussion**

We have successfully implemented a model of reversible embolic stroke that is fully MR imaging-compatible. This model has the potential to provide information on the pathophysiology of stroke related to water diffusion and blood flow changes that occur within the first few hours of stroke onset. Furthermore, the use of autologous clots, rather than balloon occlusion or use of a synthetic embolic agent, creates a model that is more amenable for the study of chemical or mechanical thrombolysis. We have seen the potential to track the physiologic response to therapy in real time.

We have measured changes in cerebral blood flow and diffusion changes in “near real time” using standard MR imaging scanners. These images are generated upon scan completion and provide immediate feedback on the status of the tissue at risk. We have been successful in all attempts to create a stroke. The location of the strokes was confirmed with x-ray angiography and the flow distributions further elucidated by MR imaging perfusion/diffusion changes. In the initial PWI/DWI scans, acquired 30 minutes after the injection of the clot, we saw slight differences in DWI (b = 1000) and ADC images. As

<table>
<thead>
<tr>
<th>Description</th>
<th>Stroke Region (mL/100 g/min)</th>
<th>Normal Contralateral (mL/100 g/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3T, stroke</td>
<td>2.72 ± 1.21</td>
<td>42.93 ± 16.70</td>
</tr>
<tr>
<td>3T stroke*, t</td>
<td>15.09 ± 4.71</td>
<td>49.56 ± 12.75</td>
</tr>
<tr>
<td>3T, stroke*</td>
<td>3.81 ± 3.77</td>
<td>46.51 ± 11.68</td>
</tr>
<tr>
<td>1.5T, stroke*</td>
<td>6.22 ± 3.36</td>
<td>27.42 ± 10.67</td>
</tr>
<tr>
<td>Mean value</td>
<td>7.22 ± 4.90</td>
<td>42.25 ± 8.64</td>
</tr>
<tr>
<td>P value</td>
<td>&lt;.0007</td>
<td></td>
</tr>
<tr>
<td>3T, control</td>
<td>51.84 ± 13.26</td>
<td>59.50 ± 14.48</td>
</tr>
</tbody>
</table>

* Treated with recombinant tissue plasminogen activator.† Recanalization was observed.
the stroke evolved, we were able to observe the increase in the hyperintensity on the $b = 1000$ images and a corresponding decrease in the ADC values (Fig 2). For the final time point that was acquired 2 hours postictally, we have found statistically significant differences in both ADC and qCBF in the regions affected by the stroke.

The model we have developed has been designed to be MR imaging-compatible so that imaging tools can be used to track the development of physiologic changes that occur as a result of the stroke. Our earliest attempts at this model were confounded by large signal intensity voids in the vicinity of the frontal sinuses of the dogs. These signal intensity dropouts were most pronounced in the gradient-echo EPI acquisitions used for the PWI bolus tracking. The location and size of the artifacts were worsened by the fact that we were using a high-field MR imaging scanner. To circumvent the problem of the field inhomogeneity, we filled the sinus with Surgilube to reduce the local field inhomogeneity. This approach allowed many more artifact-free sections to be acquired. In our studies, 9–10 sections were acquired, whereas examinations performed without filling the sinuses yielded only 2–3 usable sections. Furthermore, these sections were from the more posterior portion of the brain, making selection of the arterial input function in the MCA nearly impossible. We mixed small amounts of barium powder with the Surgilube to render it radiopaque. The opacity of the Surgilube gel allowed the interventionist to view the filling of the sinuses under x-ray guidance. Both lateral and coronal x-ray projections were acquired to ensure complete filling of the sinuses.

In our model, x-ray DSA was required both to guide the catheters for thrombus deposition and confirm MCA occlusion. To perform the MR imaging, the animal must be transported to the MR imaging scanner. The transport of the animal between the angiography suite and the MR scanner is complex and requires the coordination of several elements. It is hoped in the future that many of these steps can be eli-
tated through the use of a combined x-ray/MR imaging scanner.

The development of a full array of MR imaging catheter tracking tools that would eliminate the need of the x-ray machine would also be desirable, and several groups are actively working in this area.\textsuperscript{19–22} When these tools are perfected, it is hoped that both intravenous and intraarterial MR-guided thrombolysis can be developed and evaluated for the eventual use in humans.

We successfully re-established flow in 1 of 3 dogs that were treated with rtPA. This rate is rather low for these initial experiments, and we believe this rate may reflect some shortcomings in the animal model. For example, we terminated the experiments upon completion of the rtPA infusion. In our protocol, the rtPA was infused as a bolus plus an infusion that lasted 45 minutes; therefore, in all cases, the last MR imaging that was performed was within 1 hour of the beginning of the rtPA infusion. This may have prevented the observation of flow restoration occurring in a more delayed fashion. Second, the volume of thrombus injected was not standardized between experiments. In future studies, we will explore whether a smaller clot burden would lyse more quickly and completely.

We have applied a previously reported technique for quantification of CBF. In these experiments our average qCBF value in the unaffected region was in good agreement with previously published canine values.\textsuperscript{23} One difficulty in the use of the canine model is the relative paucity of white matter compared with the human brain. White matter has a lower metabolic demand, and therefore is perfused at roughly half the rate for gray matter. This has important consequences for the extrapolation of these data to humans. Because thresholds for cell death can potentially depend on metabolic need, the limited amount of white matter in dogs should be considered. What may be of particular interest in further experiments is the relation between the level of hypoperfusion as measured with qCBF and the recanalization rate. In the second experiment, where we observed restoration of flow, the baseline qCBF in the stroke region, though hypoperfused, was 3 times the mean value of the other dogs (roughly 4 SDs).

This study was not without limitations. First and foremost, we did not control for the volume of the blood clot that was injected. In future studies, we will determine the relation between clot burden, the degree of hypoperfusion, and the recanalization rate. This underlines the goal of this work: to create a reproducible model of embolic stroke for well-controlled experiments. In this study we have not compared our qCBF measurements with an established standard of reference, such as colored microsphere deposition.\textsuperscript{24,25} This will be the aim of future studies on our models.

Conclusion

Our study results indicate that we have developed a reproducible canine model of thromboembolic stroke that is MR imaging-compatible. Using this model, we were able to track the evolution of perfusion and diffusion changes and assess the response to MR-guided thrombolytic therapy. We measured qCBF and showed that the values obtained were in close agreement with published values in a canine model. We compared qCBF in the normal and hypoperfused regions and showed that these values were significantly different.

References


